Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131386 | 0.82 | KIF11 (0.43) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL6131385 | 0.81 | KIF11 (0.40) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL6046726 | 0.80 | KIF11 (0.46) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL6046721 | 0.79 | KIF11 (0.39) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL2385290 | 0.76 | SLC6A11 (0.46) | KIF11KCNH2SLC6A1SLC6A11KMT2A | |
| SCHEMBL2400336 | 0.76 | SLC6A11 (0.46) | KIF11KCNH2SLC6A1SLC6A11KMT2A | |
| SCHEMBL6040158 | 0.76 | SLC6A11 (0.46) | KIF11KCNH2SLC6A1SLC6A11KMT2A | |
| SCHEMBL13575115 | 0.76 | SLC6A11 (0.46) | KIF11KCNH2SLC6A1SLC6A11KMT2A | |
| SCHEMBL20371123 | 0.72 | KIF11 (0.51) | KIF11KCNH2SLC6A2SLC6A4 | |
| SCHEMBL2490410 | 0.70 | SLC6A11 (0.50) | KIF11KCNH2SLC6A1SLC6A11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685842-A2 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20040192632-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| EP-0957929-A4 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030114404-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6426335-B1 | ADMINISTERING COMPLEX OF NUCLEIC ACID LIGAND | GILEAD SCIENCES, INC. | 2002-07-30 | — | — | US | disclosed |
| US-6168778-B1 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes | NEXSTAR PHARMACEUTICALS, INC. | 2001-01-02 | — | — | US | disclosed |
| US-6051698-A | ARTIFICIAL LIGAND INCLUDES 2'FLUORO MODIFIED NUCLEOTIDES; FOR ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS AGAINST KARPOSI'S SARCOMA, TREATMENT OF MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF COLORADO, SUCCESSOR IN INTEREST TO UNIVERSITY RESEARCH CORPORATION AND/OR UNIVERSITY LICENSE EQUITY HOLDINGS, INC. | 2000-04-18 | — | — | US | disclosed |
| EP-0957929-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998018480-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192632-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | VEGFA, KDR, FLT1 | KIF11 2233/4885KCNH2 4517/4885SLC6A1 4127/4885 |
| US-20030114404-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | VEGFA, KDR, FLT1 | KIF11 2233/4885KCNH2 4517/4885SLC6A1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.